Alissa Kamens

Company: Promega Corporation

Job title: Strategic Collaborations Associate

Seminars:

Revolutionizing CRBN-Based Degraders with Next-Generation Protein Degradation Tools to Drive Selectivity in Therapeutic Development 11:30 am

Discovering how innovative modifications in molecular glues and PROTACs are transforming neosubstrate selectivity while addressing safety challenges linked to offtarget effects Exploring advanced strategies like Lumit assays and CRISPR-engineered panels that enable rapid profiling of degradation potency, paving the way for cell-type-specific targeted therapies Learning about the cutting-edge HiBiT CRISPR tagging system and Lumit assays,…Read more

day: Conference Day One